¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"heat shock response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heat-stable
    ¿­¾ÈÁ¤¼º-, ¿­ÀúÇ×-
  • heat-stable enterotoxin
    ¿­ÀúÇ×Àåµ¶¼Ò
  • initial heat
    Ãʱ⿭
  • local heat
    ±¹¼Ò¿­
  • maintenance heat
    À¯Áö¿­
  • moist heat sterilization
    ½À¿­¸ê±Õ
  • molar heat
    ¸ô¿­
  • molecular heat
    ºÐÀÚ¿­
  • radiant heat
    º¹»ç¿­
  • specific heat
    ºñ¿­(Ýïæð)
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    ¸é¿ª±â¾ï¹ÝÀÀ
  • biologic response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • delayed response
    Áö¿¬¹ÝÀÀ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • response decline
    ¹ÝÀÀ°¨¼Ò
  • emotional response
    °¨Á¤¹ÝÀÀ
  • evoked response
    À¯¹ß¹ÝÀÀ
  • response frequency
    ¹ÝÀÀÁ֯ļö
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦
  • inert response
    ºÒȰ¼º¹ÝÀÀ
  • inflammatory response
    ¿°Áõ¹ÝÀÀ
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • heat center
    ¿Â¿­ÁßÃß(è®æðñéõÒ).
  • heat collapse
    ¿­ÇãÅ»(Ëç̴̬).
  • heat collapse
    ¿­ÇãÅ»(æðúÈ÷­).
  • heat conduction
    ¿­Àüµµ(æðîîÓô).
  • heat content
    ÇÔ¿­·®(̰ËçËâ).
  • heat cramp
    ¿­°æ·Ã(æðÌâÕý).
  • heat dose equivalent
    ¿­¼±·®´ç·®
  • heat edema
    ¿­¼ººÎÁ¾(æðàõÝ©ðþ).
  • heat effect
    ¿­È¿°ú
  • heat exchange
    ¿­±³È¯(æðÎßüµ).
  • heat exchanger
    ¿­±³È¯±â(æðÎßüµÐï).
  • heat exhaustion
    ¿­ÇÇ·Î(æðùªÖÌ), ¿­Å»Áø.
  • heat exhaustion
    ¿­Å»Áø(æð÷­ò×)
  • heat exhaustion
    ¿­ÇÇ·Î, ¿­Å»Áø.
  • heat hyperpyrexia
    ¿­¼º°í¿­(æðàõÍÔæð).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • shock kidney
    ¼ï½Å(¡­ãì).
  • shock kidney
    ¼ï½Å(¡­ãì)
  • shock lung
    È£Èí ¼ïÆó(¡­øË).
  • shock lung
    È£Èí ¼ïÆó(û¼ýå¡­øË)
  • shock organ
    ¼ï±â°ü(¡­Ðïί).
  • shock organ
    ¼ï±â°ü(¡­Ðïί)
  • shock proof
    ¼ï³»¼º(¡­Ò±àõ)ÀÇ, ¹æÃæ°Ý(ÛÁõú ̪)ÀÇ.
  • shock proof
    ¼ï³»¼º(¡­Ò±àõ)ÀÇ, ¹æÃæ°Ý(ÛÁõú̪)ÀÇ
  • shock resistance
    ¼ï³»¼º(¡­Ò±àõ), Ãæ°ÝÀúÇ×¼º(õú̪î½ù÷àõ).
  • shock resistance
    ¼ï³»¼º(¡­Ò±àõ), Ãæ°ÝÀúÇ×¼º(õú̪î½ù÷àõ)
  • shock stage of grief
    ºñÅëÀÇ Ãæ°Ý´Ü°è
  • shock syndrome
    ¼ïÁõÈıº(¡­ñøý¦ÏØ).
  • shock syndrome
    ¼ïÁõÈıº(¡­ñøý¦ÏØ)
  • shock therapy
    Ãæ°Ý¿ä¹ý(õú̪ èþÛö).
  • shock therapy
    ¼ï¿ä¹ý, Ãæ°Ý¿ä¹ý(õú̪ èþÛö).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HAG heat-aggregated globulin
HBCG heat-aggregated Calmette-Guerin bacillus
HC hair cell; hairy cell; handicapped; head circumference; head compression; health care; healthy contr...
HEAT human erythrocyte agglutination test
HELP Hawaii early learning profile; Health Education Library Program; Health Emergency Loan Program; Heal...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
HSP 27 heat shock protein
HSP 65 heat shock protein
HSP-60 heat shock protein
HSC 70 heat shock protein 70
HSTF heat shock transcription factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • heat of activation
    Ȱ¼ºÈ­ ¿­
  • heat of dilution
    Èñ¼® ¿­
    ¿ë¾×À» ¿ë¸Å·Î Èñ¼®ÇÒ ¶§ ¹ß»ýÇÏ´Â ¿­·®. º¸Åë 1 molÀÇ ¿ëÁú¿¡ ´ëÇÏ¿© ¹ß»ýÇÏ´Â ¿­·®À¸·Î ³ªÅ¸³½´Ù. Èñ¼® ¿­Àº Èñ¼®ÇÏ´Â ¿ë¸ÅÀÇ ¾ç¿¡ µû¶ó ´Ù¸£±â ¶§¹®¿¡, ¿ë¸ÅÀÇ ¾çÀ» ¸í±âÇϰųª óÀ½°ú ¸¶Áö¸· ³óµµ¸¦ Ç¥½ÃÇØ¾ß ÇÑ´Ù. ¶Ç Èñ¼® ¿­ÀÌ À½ÀÌ µÉ ¶§°¡ Àִµ¥, À̰ÍÀº ¾×À» Èñ¼®ÇÏ¸é ³Ã°¢µÇ´Â °æ¿ì, Áï ¿­ÀÌ Èí¼öµÇ´Â °æ¿ì¿¡ ÇØ´çÇÑ´Ù.
  • heat of evaporation
    Áõ¹ß ¿­
    ¾×ü ¹°ÁúÀÌ Áõ¹ßÇϸ鼭 »ý±â´Â ¿­.
  • heat of hydration
    ¼öÈ­ ¿­
    1 molÀÇ À̿ ¶Ç´Â ºÐÀÚ°¡ ¼öÈ­µÉ ¶§ Èí¼ö ¶Ç´Â ¹ß»êÇÏ´Â ¿­·®. ÀϹÝÀûÀ¸·Î´Â Èí¿­·®À¸·Î ³ªÅ¸³½´Ù. ¼öÈ­´Â ¼ö¿ë¾× ¼Ó¿¡¼­ À̿ ¶Ç´Â ºÐÀÚ°¡ ¹° ºÐÀÚ¿Í Á¤Àü±âÀûÀ¸·Î »óÈ£ÀÛ¿ëÀ» ÇÏ¿© °áÇÕÇØ ÀÖÀ¸¹Ç·Î, Áø°ø ¼Ó¿¡ ÀÖ´Â À̿ ¶Ç´Â ºÐÀÚ¸¦ ¼ø¼ö ¼Ó¿¡ ³Ö¾î ÃøÁ¤ÇÏ¸é µÇ´Âµ¥, ½ÇÁ¦·Î´Â °ï¶õÇϹǷÎ, º»-ÇϹö-ÆÄ¾á½ºÀÇ ¼øÈ¯ °úÁ¤À̶ó°í ÇÏ´Â ¿­¿ªÇÐÀû °úÁ¤À» ÀÌ¿ëÇÏ¿© »êÃâÇÑ´Ù.
  • heat of maintenance
    À¯Áö ¿­
  • heat of reaction
    ¹ÝÀÀ ¿­
  • heat of shortening
    ´ÜÃà ¿­
  • heat of sublimation
    ½ÂÈ­ ¿­
    ±âü°¡ ȤÀº °íü°¡ ½ÂÈ­Çϸ鼭 ¹ß»ýÇÏ´Â ¿­.
  • heat pain
    ¿­Åë
    °¡¿­À̳ª ³Ã°¢¿¡ ´ëÇØ ÇǺΰ¡ ÀÏÁ¤ ¿ªÄ¡ ÀÌ»óÀÎ °æ¿ì Åë°¢À¸·Î ÀÎÁöÇØ ÅëÁõÀ» ´À³¢´Â °Í.
  • heat production
    ¿­ »ý»ê
  • heat pulse
    ¿­ ÀÚ±Ø
  • heat resisting alloy
    ³»¿­ ÇÕ±Ý
    °í¿Â¿¡¼­ È­ÇÐÀû, ¹°¸®ÀûÀ¸·Î ¾ÈÁ¤µÇ°í ¶Ç ±â°èÀû ¼ºÁúÀÌ ¶Ù¾î³ª °í¿Â¿¡¼­ÀÇ »ç¿ë¿¡ °ßµð´Â Á¶°ÇÀ» ±¸ºñÇÏ´Â ÇÕ±Ý.
  • heat reversible
    ¿­ °¡¿ª¼ºÀÇ
    ¿­À» °¡ÇÏ¸é ¿ø·¡ÀÇ »óÅ·Πµ¹¾Æ¿À´Â.
  • heat syncope
    ¿­ ½Ç½Å
    ÇǺΠÇ÷°üÀÇ È®Àå°ú ÇÔ²² Àü½Å ¹× ³ú Ç÷¾ÐÀÇ ÀúÇϰ¡ ÀϾ °©ÀÚ±â ÀǽÄÀ» ÀÒ´Â °æ¿ì¸¦ ¸»ÇÑ´Ù. ¼öÃà±â Ç÷¾ÐÀº ´ë°³ 100mmHg ÀÌÇϰ¡ µÇ¸ç, ´ëü·Î ½Ç½Å Àü¿¡ 2½Ã°£ ÀÌ»ó ½ÉÇÑ À°Ã¼ ³ëµ¿À» ÇÑ °æ·ÂÀÌ ÀÖ´Ù. ÇǺδ Â÷°í ÃàÃàÇÏ¸ç ¸Æ¹ÚÀº ¾àÇÏ°Ô ´À²¸Áø´Ù. Ä¡·á´Â ¼­´ÃÇÑ °÷¿¡ ´©¿ö ¾ÈÁ¤À» ÃëÇÏ°Ô ÇÏ°í °æ±¸·Î ¼öºÐÀ» °ø±ÞÇϸç, ÇÊ¿äÇÏ¸é ¼ö¾×À» Á¤¸Æ ÁÖ»çÇÑ´Ù.
  • heat transfer
    ¿­ Àü´Þ
    µ¿ÀǾî=heat transmission.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
Cushing response A rise in systemic blood pressure when the intracranial pressure acutely increases, usually in excess of 50% of the systolic arterial pressure.
Synonym: Cushing effect, Cushing response.
(05 Mar 2000)
primary antibody response <immunology> Antibodies made upon first exposure to an antigen, mostly of the class IgM.
(05 Mar 1998)
primary immune response <immunology> The immune response to the first challenge by a particular antigen. Usually less extensive than the secondary immune response, being slower and shorter lived with smaller amounts of lower affinity antibody being produced.
(18 Nov 1997)
Henry-Gauer response Inhibition of antidiuretic hormone secretion due to a rise in atrial pressure which stimulates atrial stretch receptors.
(05 Mar 2000)
satiety response Behavioural response associated with the achieving of gratification.
(12 Dec 1998)
psychogalvanic response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
secondary antibody response An antibody made upon second (subsequent) exposure to an antigen, mostly of the class IgG.
(09 Oct 1997)
secondary immune response The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen.
(18 Nov 1997)
humoral immune response <immunology> Those immune responses mediated by antibody.
(06 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á